Author

Richard G. Willey

Institution: Alnylam Pharmaceuticals (United States)

Observed institution: Alnylam Pharmaceuticals (United States)

OpenAlex ID: A5108930846

ILLUMINATE-C, a Single-Arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD Stages 3b-5, Including Those on Hemodialysis

2021 · Mini Michael, Jaap Groothoff, et al. · Journal of the American Society of Nephrology · 3

Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial

2023 · John C. Lieske, Daniella Magen, et al. · Journal of the American Society of Nephrology · 1

Kidney Function and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1 Treated with Long-Term Lumasiran

2024 · Michael J. Somers, Arnaud Devresse, et al. · Journal of the American Society of Nephrology

Long-Term Efficacy and Safety of Lumasiran in Patients with Primary Hyperoxaluria Type 1: Final Analysis of the ILLUMINATE-A Trial

2024 · Jeffrey Saland, John C. Lieske, et al. · Journal of the American Society of Nephrology

Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study

2023 · John C. Lieske, Jaap Groothoff, et al. · Journal of the American Society of Nephrology

Lumasiran for Patients With Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-Month Analysis of the Phase 3 ILLUMINATE-C Trial

2022 · Yaacov Frishberg, Mini Michael, et al. · Journal of the American Society of Nephrology

Works count: 6

Citation count: 4

H-index: 1

I10-index: